BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 12669962)

  • 1. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model.
    Pan XQ; Wang H; Lee RJ
    Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.
    Riviere K; Huang Z; Jerger K; Macaraeg N; Szoka FC
    J Drug Target; 2011 Jan; 19(1):14-24. PubMed ID: 20353291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes.
    Xiang G; Wu J; Lu Y; Liu Z; Lee RJ
    Int J Pharm; 2008 May; 356(1-2):29-36. PubMed ID: 18258394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo antitumor activity of folate receptor-targeted liposomal daunorubicin in a murine leukemia model.
    Pan XQ; Lee RJ
    Anticancer Res; 2005; 25(1A):343-6. PubMed ID: 15816557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index.
    Scomparin A; Salmaso S; Eldar-Boock A; Ben-Shushan D; Ferber S; Tiram G; Shmeeda H; Landa-Rouben N; Leor J; Caliceti P; Gabizon A; Satchi-Fainaro R
    J Control Release; 2015 Jun; 208():106-20. PubMed ID: 25869964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
    Pan XQ; Zheng X; Shi G; Wang H; Ratnam M; Lee RJ
    Blood; 2002 Jul; 100(2):594-602. PubMed ID: 12091353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug.
    Stevens PJ; Sekido M; Lee RJ
    Pharm Res; 2004 Dec; 21(12):2153-7. PubMed ID: 15648245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isomeric folate-conjugated polymeric micelles bind to folate receptors and display anticancer effects.
    Dong Q; Xie ZX; Xie C; Lu WY; Zhang Q; Li X; Liu M
    Asian Pac J Cancer Prev; 2014; 15(17):7363-9. PubMed ID: 25227843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation, characterization and pharmacokinetics of folate receptor-targeted liposomes for docetaxel delivery.
    Zhai G; Wu J; Xiang G; Mao W; Yu B; Li H; Piao L; Lee LJ; Lee RJ
    J Nanosci Nanotechnol; 2009 Mar; 9(3):2155-61. PubMed ID: 19435095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin loaded pH-sensitive micelle: antitumoral efficacy against ovarian A2780/DOXR tumor.
    Kim D; Lee ES; Park K; Kwon IC; Bae YH
    Pharm Res; 2008 Sep; 25(9):2074-82. PubMed ID: 18449626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of a folate receptor-targeted immunoglobulin G-doxorubicin conjugate.
    Yang T; Xu L; Li B; Li W; Ma X; Fan L; Lee RJ; Xu C; Xiang G
    Int J Nanomedicine; 2017; 12():2505-2515. PubMed ID: 28408821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folate receptor targeted biodegradable polymeric doxorubicin micelles.
    Yoo HS; Park TG
    J Control Release; 2004 Apr; 96(2):273-83. PubMed ID: 15081218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of folate-linked liposomal doxorubicin to its antitumor effect in mice.
    Yamada A; Taniguchi Y; Kawano K; Honda T; Hattori Y; Maitani Y
    Clin Cancer Res; 2008 Dec; 14(24):8161-8. PubMed ID: 19088031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
    Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
    Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate-modified poly(2-ethyl-2-oxazoline) as hydrophilic corona in polymeric micelles for enhanced intracellular doxorubicin delivery.
    Qiu LY; Yan L; Zhang L; Jin YM; Zhao QH
    Int J Pharm; 2013 Nov; 456(2):315-24. PubMed ID: 24016742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of doxorubicin resistance in multidrug-resistance cells by targeted liposomes combined with hyperthermia.
    Gaber MH
    J Biochem Mol Biol Biophys; 2002 Oct; 6(5):309-14. PubMed ID: 12385965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice.
    Gabizon A; Horowitz AT; Goren D; Tzemach D; Shmeeda H; Zalipsky S
    Clin Cancer Res; 2003 Dec; 9(17):6551-9. PubMed ID: 14695160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A folate receptor-targeted liposomal formulation for paclitaxel.
    Wu J; Liu Q; Lee RJ
    Int J Pharm; 2006 Jun; 316(1-2):148-53. PubMed ID: 16564654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.